Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Central Neuropathic Pain, Multiple Sclerosis

In brief

The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses of AVP-923 capsules in the treatment of central neuropathic pain in participants with multiple sclerosis.

Key facts

Study ID
NCT01324232
Run by
Avanir Pharmaceuticals
People needed
209
Starts
2011-09-08
Expected to finish
2013-09-26
Last updated by the study team
2021-11-22

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.